Day: November 15, 2019

Företagsmeddelande, Insiderinformation, Helsingfors, 15 november 2019, kl. 18.30 (EET)Nexstim Abp: Totalt 15 687 350 aktier tecknats i den riktade aktieemissionenI enlighet med styrelsens beslut i Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”Bolaget”) som meddelades den 11 november 2019, har 15 687 350 nya aktier tecknats. Genom godkännandet av dessa teckningar kommer Bolaget att tillföras cirka 1,8 miljoner euro från den riktade emissionen exluderande garantiersättningar samt andra avgifter och kostnader.Som Bolaget informerade om den 21 oktober 2019, 6 november 2019 och 11 november 2019, har teckningsoptionerna som emitterades under våren 2019 inlösts och Bolaget har genomfört en riktad emission. Genom teckningsoptionerna och den riktade emissionen har Bolaget anskaffat totalt cirka 2,9 miljoner euro innan avgifter och kostnader,...

RECORDATI:  CHMP ADOPTS POSITIVE OPINION FOR ISTURISA® (OSILODROSTAT)Milan, 15 November 2019 – Recordati announces that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Isturisa®, indicated for the treatment of endogenous Cushing’s syndrome in adults. The benefits with Isturisa® are its ability to control or normalise raised cortisol levels. The active substance of Isturisa® is osilodrostat, a cortisol synthesis inhibitor. Osilodrostat works by inhibiting 11-beta-hydroxylase, an enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. Isturisa® will be available as 1-mg, 5-mg and 10-mg film-coated tablets.Detailed recommendations for the use of this product will be described in the summary of...

Milano, 15 novembre 2019 – Recordati annuncia che l’EMA (Eurpean Medicines Agency) ha comunicato a Novartis che il Committe for Medicianl Products for Human Use (CHMP) ha emesso una opinione positiva, raccomandando l’attribuzione di una autorizzazione all’immissione in commercio per il prodotto farmaceutico Isturisa®, indicato per il trattamento della sindrome di Cushing endogena negli adulti. I benefici di Isturisa® sono la sua capacità di controllare o normalizzare i livelli aumentati di cortisolo. Il principio attivo di Isturisa® è l’osilodrostat, un inibitore della produzione di cortisolo. Agisce inibendo l’11 beta-idrossilasi, un enzima che catalizza la fase finale della sintesi di cortisolo nella corteccia surrenale. Isturisa® sarà disponibile in compresse rivestite con film di 1 mg, 5 mg e 10 mg.Le raccomandazioni per l’utilizzo...

MONTREAL, Nov. 15, 2019 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL; TSX and NYSE) will be holding its 2019 Institutional Investor and Analyst Conference in San Pedro Sula, Honduras on November 19-21, 2019, as previously announced by the Company on May 22, 2019.  Starting at 8:00 PM EST, on November 19, Gildan’s senior management team will be providing a strategic overview of its business.  A live audio webcast with presentation slides, and a replay, will be accessible through the Company’s website at http://www.gildancorp.com/events.  Management’s audio presentation can also be accessed by dialing (877) 282-2924 (Canada & U.S.) or (470) 495-9480 (international) and entering passcode 9088906#.  A replay will be available for 7 days starting at 11:00 PM ET by dialing (855) 859-2056 (Canada & U.S.) or (404) 537-3406 (international)...

MONTRÉAL, 15 nov. 2019 (GLOBE NEWSWIRE) — Les Vêtements de Sport Gildan Inc. (GIL: TSX et NYSE) tiendra sa conférence 2019 à l’intention des investisseurs institutionnels et analystes à San Pedro Sula, au Honduras, du 19 au 21 novembre 2019, comme annoncé précédemment par la Société le 22 mai 2019. À partir de 20 h 00 HE, le 19 novembre, la haute direction de Gildan donnera un aperçu stratégique de ses activités. Une diffusion audio en direct sur le Web avec des diapositives de présentation et une retransmission seront accessibles sur le site Web de la société à l’adresse http://www.gildancorp.com/fr/evenements.La présentation audio des membres de la direction est également accessible en composant le (877) 282-2924 (Canada et États-Unis) ou le (470) 495-9480 (international) et en saisissant le code 9088906 #. Une retransmission...

15.11.2019 at 18:30UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 15.11.2019The shares held by United Bankers Corporation on 15.11.2019:On behalf of United Bankers CorporationAntti Salakka         Mikko VirtanenFor more information, please contact:Patrick Anderson, toimitusjohtaja, United Bankers OyjSähköposti: patrick.anderson@unitedbankers.fiPuhelin: 0400 244 544,09 25 380 236www.unitedbankers.fiAttachmentUB SBB 15112019

15.11.2019 klo 18:30UNITED BANKERS OYJ:n OMIEN OSAKKEIDEN HANKINTA 15.11.2019Yhtiön hallussa olevat omat osakkeet 15.11.2019:United Bankers Oyj:n puolestaAntti Salakka         Mikko VirtanenLisätietoja antaa:Patrick Anderson, toimitusjohtaja, United Bankers OyjSähköposti: patrick.anderson@unitedbankers.fiPuhelin: 0400 244 544,09 25 380 236www.unitedbankers.fiLiiteUB SBB 15112019

AttachmentLAT1V_15.11_trades

LiiteLAT1V_15.11_trades

Net asset value (NAV) of Baltic Horizon Fund (the Fund) unit as at end of October 2019 amounted to 1.3230 EUR per unit. Compared to the previous month, NAV decreased by -1.27%. The NAV decrease was mainly affected by a declared dividend of EUR 3.06 million recognized in October 2019. Eliminating dividend distribution effect to NAV, the NAV increase from operating performance and positive cash flow hedge reserve movement during the month would have been +0.75% compared to the previous month. The Fund earned an unaudited consolidated net profit of EUR 1,125 thousand in October 2019, which is 9.1% higher than in September 2019. Growth in the net profit is related to the acquisition of the North Star Business Centre in Vilnius, Lithuania.Additional information:  Tarmo KarotamBaltic Horizon Fund managerE-mail tarmo.karotam@nh-cap.comwww.baltichorizon.comThe...